GlassScriptPhysician profile
Anna Jing Shi
NPI 1194093971
$23,113.04
in general payments reported to CMS, 2019-2025
25 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $691 · 2021: $970 · 2022: $1,004 · 2023: $1,406 · 2024: $4,668 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $7,290 · Travel and Lodging: $402 · Education: $62.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,126.08 |
| Food and Beverage | $7,290.08 |
| Travel and Lodging | $402.35 |
| Education | $62.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $12,373.94 | 2019-2025 | Travoprost Intraocular Implant - Idose, Idosetr, Idose |
| Rxsight INC | $3,095.25 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Sight Sciences, INC. | $2,218.61 | 2021-2025 | Omni Surgical System, Tearcare System |
| Alcon Vision LLC | $1,279.14 | 2019-2025 | Hydrus Microstent, Clareon, Tryptyr |
| Abbvie INC. | $694.51 | 2022-2025 | Durysta |
| Sun Pharmaceutical Industries INC. | $631.30 | 2019-2025 | Cequa |
| Allergan, INC. | $512.96 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $450.49 | 2019-2021 | |
| Biotissue Holdings INC. | $333.34 | 2020-2025 | |
| Tarsus Pharmaceuticals, INC. | $332.66 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $211.83 | 2022-2025 | Vyzulta, Miebo |
| Eyevance Pharmaceuticals LLC | $178.28 | 2019-2021 | |
| Astellas Pharma US INC | $160.26 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $116.16 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $97.23 | 2021-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $82.45 | 2024-2025 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $65.11 | 2021 | |
| Thea Pharma INC. | $63.10 | 2025 | Iyuzeh |
| Horizon Therapeutics Plc | $60.74 | 2023 | Tepezza |
| Beaver-Visitec International, INC. | $44.41 | 2023 | |
| Dompe US, INC. | $37.98 | 2021-2025 | Oxervate |
| Merz North America, INC. | $22.03 | 2020 | |
| Amgen INC. | $20.71 | 2024 | Tepezza |
| Quidel Corporation | $17.18 | 2020 | |
| Iridex Corporation | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Shi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.